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ABSTRACT
Background. Several clinical risk scores (CRSs) for the
outcome of patients with colorectal liver metastases have
been validated, but not in patients undergoing neoadjuvant
chemotherapy. Therefore, this study evaluates the predic-
tive value of these CRSs in this specific group.
Methods. Between January 2000 and December 2008, all
patients undergoing a metastasectomy were analyzed and
divided into two groups: 193 patients did not receive
neoadjuvant chemotherapy (group A), and 159 patients
received neoadjuvant chemotherapy (group B). In group B,
the CRSs were calculated before and after administration
of neoadjuvant chemotherapy. Results were evaluated by
using the CRSs proposed by Nordlinger et al., Fong et al.,
Nagashima et al., and Konopke et al.
Results. In groups A and B, the overall median survival was
43 and 47 months, respectively (P = 0.648). In group A, all
CRSs used were of statistically significant predictive value.
Before administration of neoadjuvant chemotherapy, only
the Nordlinger score was of predictive value. After admin-
istration of neoadjuvant chemotherapy, all CRSs were of
predictive value again, except for the Konopke score.
Conclusions. Traditional CRSs are not a reliable prog-
nostic tool when used in patients before treatment with
neoadjuvant chemotherapy. However, CRSs assessed after
the administration of neoadjuvant chemotherapy are useful
to predict prognosis.
In patients with colorectal cancer, about 50–60% will
develop metastatic disease. Synchronous metastases are
present in 25% of colorectal cancer patients.1,2 Nowadays,
neoadjuvant chemotherapy is increasingly used for patients
with colorectal liver metastases (CRLM). New systemic
regimes are highly effective, and response rates of 50–80%
have been reported; they appear to convert 10–30% of the
formerly irresectable CRLM to a resectable size.3–6 Several
clinical risk scores (CRSs) for the outcome of patients with
CRLM have been published.7–16 A CRS is a predictive tool
for patients with CRLM who undergo resection.4,8–12,17–22
CRSs were initially used to predict the prognosis of patients
with CRLM considered for surgery. In addition, CRSs are
used to stratify patients into risk categories, to compare
patient cohorts from different studies and institutions, and
to select patients for different treatment protocols.
However, the predictive value of these CRSs has not
been assessed in the specific group of patients receiving
neoadjuvant chemotherapy before resection of CRLM. It is
possible that the traditional CRSs, applied before admin-
istration of neoadjuvant chemotherapy, may no longer be
capable of correctly predicting the outcome in patients
receiving neoadjuvant chemotherapy.4,19,20
Therefore, in the present study, four widely used CRSs
are applied in a cohort of patients with CRLM who
received neoadjuvant chemotherapy before resection, to
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evaluate whether neoadjuvant chemotherapy influences the
predictive value of CRSs.
PATIENTS AND METHODS
Between January 2000 and December 2008, all con-
secutive patients who underwent liver resection for CRLM
were analyzed. Patient characteristics were collected ret-
rospectively from a prospectively recorded database. Two
groups were created: group A (patients without neoadju-
vant chemotherapy; n = 193) and group B (patients with
neoadjuvant chemotherapy; n = 159). In group B, the
CRSs were calculated before (B1) and after (B2) admin-
istration of neoadjuvant chemotherapy.
The prospective database comprises data on age, gender,
primary tumor site, pathological primary tumor and lymph
node stage, time between detection of primary tumor and
liver metastases, type of surgery, location, maximum
number and size of liver metastases on computed tomo-
graphic scan and pathology, carcinoembryonic antigen
(CEA) levels, radicality of surgical margin, and extrahe-
patic disease.
Ours is a referral hospital; perioperative chemotherapy is
not administered as a standard treatment protocol for patients
with CRLM. Most of our patients have already received
neoadjuvant chemotherapy in the referring hospital. In our
center, the indication for neoadjuvant chemotherapy is
twofold: in case of initially difficult/unresectable liver
metastases, or in case of multiple synchronous metastases
numbering C4. It is our policy not to resect in case of tumor
progression during chemotherapy. Neoadjuvant chemo-
therapy protocols comprise oxaliplatin-based combination
therapies with or without bevacizumab. None of the patients
in the present study received adjuvant chemotherapy. The
duration of the chemotherapy was at minimum 3 cycles. If
there were resectable metastases, chemotherapy was given to
a maximum of 6 cycles or was stopped after 3 cycles in case
of disappearing metastases. In case of unresectable disease,
chemotherapy was provided until resectable status was
achieved.
CRSs
Four widely used CRSs were evaluated (Table 1).8,9,11,12
The Nordlinger score includes seven risk factors and defines
three risk groups, but, as proposed by Nordlinger et al., we
used only six risk factors. Fong’s score includes five risk
factors and defines two risk groups. Nagashima’s score
includes five risk factors and defines three risk groups. The
Konopke score includes three risk factors and defines three
risk groups. These four CRSs were applied on our data to
evaluate each of the scores.
Outcome
Overall survival (OS) was defined as the interval (in
months) between resection of CRLM and death, or the date
of last follow-up. Disease-free survival (DFS) was defined
as the interval (in months) between resection of CRLM and
intra- and/or extrahepatic recurrence, death without recur-
rence, or date of last follow-up without recurrence.
Statistical Analysis
Descriptive statistics are expressed as median (range).
Comparison between the categorical variables was made
with the chi-square test. Pre- and postchemotherapy vari-
ables are expressed as mean ± standard deviation (SD) and
compared with the paired t-test. Survival analysis was
performed by the Kaplan-Meier method. Comparison
between survival curves was made with log rank tests. For
missing values, multiple imputation was used.
SPSS software, version 17.0 (SPSS, Chicago, IL), was
used for statistical analysis; a P-value of B0.05 is consid-
ered statistically significant.
RESULTS
Between January 2000 and December 2008, a total
of 352 patients underwent liver resection for CRLM
(Table 2). The median follow-up was 32 (range 0–121)
months. Median age was 63 (range 30–86) years. The
clinical characteristics are presented in Table 2. The
median DFS was 11 (95% confidence interval [CI] 9–13)
months, and the median OS was 46 (95% CI 39–53)
months. Neoadjuvant chemotherapy was provided to 159
patients (45.2%). Chemotherapy was given in a median of
6 (1–15) courses. In total, 43 patients received more than 6
courses with a median of 9 (7–15) courses.
Pre- and Postchemotherapy
In patients receiving neoadjuvant chemotherapy, the
variables size of metastases, CEA level, number of
metastases, bilobar disease, and extrahepatic disease were
analyzed before and after administration of neoadjuvant
chemotherapy. Before neoadjuvant chemotherapy, the
mean ± SD size, CEA level, and number of metastases
were 3.98 ± 2.62 cm, 171 ± 568 lg/l and 3.19 ± 1.95,
respectively. Before neoadjuvant chemotherapy, 83
patients had bilobar disease and 22 had extrahepatic dis-
ease. After neoadjuvant chemotherapy, the mean ± SD
size, CEA level, and number of metastases were
2.83 ± 2.45 cm, 21 ± 48 lg/l and 2.64 ± 1.96, respec-
tively. After chemotherapy, 81 patients had bilobar disease
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and 22 patients still had extrahepatic disease. To determine
the size of the metastases the postchemotherapy abdominal
scans were assessed. To determine the number of metas-
tases the postsurgery pathological report was examined.
Only when complete response was reported did the number
of metastases decrease. The difference between pre- and
postneoadjuvant chemotherapy was significant for the size
of metastases, CEA level, and the number of metastases
(P \ 0.001, P = 0.001, and P \ 0.001, respectively). No
significant difference was found between bilobar disease
and extrahepatic disease before and after neoadjuvant
chemotherapy (P = 0.832 and P = 0.999, respectively).
Nordlinger
The CRS of Nordlinger could be applied to 150 patients
in group A and to 101 patients in group B (Table 1).
In group A the median DFS was 16 (95% CI 12–20)
months, and the median OS was 48 (95% CI 33–63)
months (Tables 3, 4). In group A, the Nordlinger score was
of statistically significant predictive value. There was a
significant difference between the CRS subgroups for DFS
and OS (P = 0.028 and P = 0.006, respectively). Because
of the small numbers of patients, the CRS subgroup 3 (CRS
5–6) was pooled together with subgroup 2 (CRS 3–4). In
group B the median DFS was 13 (95% CI 9–17) months
and the median OS was 65 (95% CI 44–86) months. The
Nordlinger score was of predictive value both before and
after administration of neoadjuvant chemotherapy. In these
CRS subgroups a significant difference was found in OS:
P = 0.007 before neoadjuvant chemotherapy and
P = 0.010 after neoadjuvant chemotherapy.
Fong
The CRS of Fong could be applied to 150 patients in
group A and to 101 patients in group B (Table 1).
In group A the median DFS was 16.0 (95% CI 12–20)
months, and the median OS was 48 (95% CI 33–63)
months (Tables 3, 4). There was a significant difference
TABLE 1 Clinical risk score
Scale Clinical score criteriaa Criteria Score
Nordlinger 1. Age C60 years
2. Extension into the serosa of the primary cancer
3. Lymphatic spread of the primary cancer
4. Interval less than 2 years from primary tumor to
metastases
5. Number of metastases C4
6. Largest size of liver metastasis C5
Exclusion criteria
1. Incomplete liver tumor resection
2. Extrahepatic tumor involvement
• 0–2 risk factors ‘‘low
risk’’
• 3–4 risk factors
‘‘intermediate risk’’
• 5–6 risk factors ‘‘high
risk’’
Fong 1. Number of liver metastases [1
2. Preoperative CEA level [200 ng/ml
3. Largest size of liver metastasis C5
4. Lymph node–positive primary tumor
5. Interval from primary tumor resection to diagnosis of the
liver metastases \12 months
Exclusion criteria
1. Positive resection margin
2. Preoperative extrahepatic disease
• 0–2 risk factors
• 3–4–5 risk factors
Nagashima 1. Serosal invasion of primary tumor
2. Positive lymph node of primary tumor
3. Number of hepatic metastases C2
4. Diameter of hepatic metastases C5 cm
5. Resectable extrahepatic metastases.
Inclusion criteria
1. Expected radical excision (including
extrahepatic metastases)
• 0–1 grade 1
• 2–3 grade 2
• C4 grade 3
Konopke 1. Number of liver metastases C4
2. CEA level (ng/ml) C200
3. Synchronous liver metastases
Exclusion criteria
1. Recurrent liver metastases
2. Simultaneous extrahepatic tumor
recurrence
3. Simultaneous local ablative therapy
4. Intraoperative dissemination of tumor
cells
5. Macroscopically or microscopically
incomplete resection
• 0 low risk
• 1 intermediate risk
• C2 high risk
CEA carcinoembryonic antigen
a Each criterion is assigned 1 point
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between the CRS subgroups for DFS and OS (P \ 0.001
and P = 0.001, respectively).
In group B the median DFS was 13 (95% CI 9–17)
months, and the median OS was 65 (95% CI 44–86)
months. Fong’s score was not of statistically significant
predictive value when calculated before neoadjuvant che-
motherapy. In the CRS subgroups no significant difference
was found for OS (P = 0.592). After neoadjuvant che-
motherapy, a significant difference (P = 0.003) was found
between the CRS subgroups for OS.
Nagashima
The CRS of Nagashima could be applied to 193 patients
in group A and to 159 patients in group B (Table 1).
In group A, the median DFS was 14 (95% CI 11–17)
months and the median OS was 43 (95% CI 34–52) months
(Tables 3, 4). In the CRS subgroups a significant difference
was found for DFS and OS (P = 0.001 and P = 0.001,
respectively). Because of the small numbers of patients, the
CRS subgroup 3 (CRS C 4) was pooled together with
subgroup 2 (CRS 2–3).
In group B, the median DFS was 9 (95% CI 7–11)
months and for OS the median was 47 (95% CI 33–61)
months. When calculated before neoadjuvant chemother-
apy Nagashima’s score was not of significant predictive
value, and no significant difference (P = 0.122) was found
between the CRS subgroups for OS. However, after neo-
adjuvant chemotherapy, a significant difference (P =
0.001) was found between the CRS subgroups for OS.
Konopke
The CRS of Konopke could be applied to 145 patients in
group A and to 69 patients in group B (Table 1).
In group A the median DFS was 16 (95% CI 11–21)
months, and the median OS was 51 (95% CI 37–65)
months (Tables 3, 4). Between the CRS subgroups a sig-
nificant difference was found in DFS and OS (P = 0.002
and P = 0.024, respectively).
In group B the median DFS was 21 (95% CI 3–39)
months, and the median OS was 65 months (the 95% CI
could not be calculated by the SPSS software). There was
no significant difference between the subgroups in OS,
TABLE 2 Characteristics of the study patients
Characteristic All patients (n = 352) Patients without chemotherapy
(group A) (n = 193)
Patients with chemotherapy
(group B) (n = 159)
Value % or range Value % or range Value % or range
Male 218 62 122 63 96 60
Median age (years) 63 30–86 64 30–86 62 36–84
Primary tumor
Rectal cancer 167 47 90 47 77 48
T3 259 74 140 73 119 75
T4 30 9 15 8 15 9
Missing before imputation 6 2
Positive lymph node 205 58 110 57 92 58
Missing before imputation 6 2
Liver metastases
Synchronous 172 49 55 29 117 74
Median diameter (cm) 3.5 0.5–18 3.5 0.9–15 3.4 0.5–18
Missing before imputation 5 1
Median no. of metastases 2 1–10 1 1–8 3.0 1–10
Missing before imputation 2 1
Bilobar 135 38 52 27 83 52
Extrahepatic 29 8 7 44 22 14
Incomplete resection 72 21 40 21 32 20
Missing before imputation 7 2
Overall survival (months) 46 95% CI 39–53 43 95% CI 34–52 47 95% CI 33–61
Disease-free survival (monthos) 11 95% CI 9–13 14 95% CI 11–17 9 95% CI 7–11
CI confidence interval
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TABLE 3 Kaplan-Meyer analysis of disease-free survival in patients with and without chemotherapy
Scoring
system
Without neoadjuvant chemotherapy
(group A)
Before neoadjuvant chemotherapy
(group B1)
After neoadjuvant chemotherapy
(group B2)
n Median
time
(months)
95%
CI
3 years
(%)
P-value n Median
time
(months)
95%
CI
3 years
(%)
P-value n Median
time
(months)
95%
CI
3 years
(%)
P-value
Nordlinger 150 16 12–20 40 0.028a 101 13 9–17 36 0.458a 101 13 9–17 36 0.173a
0–2 87 18 0–43 46 37 13 5–22 38 47 14 7–23 40
3–4 59 15 11–19 34 60 13 6–20 36 53 12 7–17 33
5–6 4 4 0–12 0 4 3 0–9 0 1 – – –
Fong 150 16 12–20 40 \0.001 101 13 9–17 36 0.603 101 13 9–17 36 0.096
0–2 123 21 3–39 47 54 13 3–23 38 70 14 6–22 39
3–5 27 10 8–12 11 47 12 7–17 34 31 7 3–11 29
Nagashima 193 14 11–17 35 0.001a 159 9 7–11 26 0.030a 159 9 7–11 26 0.001a
0–1 112 18 10–26 44 61 13 6–20 32 72 14 8–20 34
2–3 77 10 7–13 24 94 7 5–9 22 84 6 5–7 18
C4 4 11 5–17 0 4 6 – 25 3 6 – –
Konopke 145 16 11–21 41 0.002 69 21 3–39 45 0.354 69 21 3–39 45 0.663
0 91 37 12–61 51 13 41 – 61 15 41 0–83 59
1 47 14 10–18 29 38 21 0–44 45 46 20 6–34 41
C2 7 9 0–22 0 18 6 0–14 32 8 6 0–14 38
CI confidence interval, CRS clinical risk score
a As a result of the small numbers of patients, CRS subgroup 3 (CRS C4) was pooled together with subgroup 2 (CRS 2–3)
TABLE 4 Kaplan-Meyer analysis of overall survival in patients with and without chemotherapy
Scoring
system
Without neoadjuvant chemotherapy
(group A)
Before neoadjuvant chemotherapy
(group B1)
After neoadjuvant chemotherapy
(group B2)
n Median
time
(months)
95%
CI
5 years
(%)
P-value n Median
time
(months)
95%
CI
5 years
(%)
P-value n Median
time
(months)
95%
CI
5 years
(%)
P-value
Nordlinger 150 48 33–63 45 0.006a 101 65 44–86 53 0.007a 101 65 44–86 53 0.010a
0–2 87 66 36–96 51 37 65 NR 66 47 65 53–77 65
3–4 59 42 23–61 39 60 47 20–74 46 53 46 29–63 41
5–6 4 18 0–49 0 4 18 NR 0 1 – – –
Fong 150 48 33–63 45 0.001 101 65 44–86 53 0.592 101 65 44–86 53 0.003
0–2 123 64 40–88 52 54 55 37–73 48 70 65 NR 58
3–5 27 34 31–37 21 47 65 9–121 60 31 29 16–42 41
Nagashima 193 43 34–52 38 0.001a 159 47 33–61 47 0.122a 159 47 33–61 47 0.001a
0–1 112 54 38–70 47 61 55 39–71 47 72 65 43–87 56
2–3 77 33 23–43 28 94 43 18–68 47 84 335 26–44 38
C4 4 34 20–48 0 4 23 8–37 0 3 23 20–26 0
Konopke 145 51 37–65 45 0.024 69 65 NR 56 0.092 69 65 NR 56 0.505
0 91 66 39–93 52 13 NR – 60 15 NR – 63
1 47 42 36–48 41 38 65 44–86 60 46 65 41–89 55
C2 7 41 18–64 0 18 32 27–37 45 8 32 12–52 45
CI confidence interval, NR not reached, CRS clinical risk score
a As a result of the small numbers of patients, CRS subgroup 3 (CRS C4) was pooled together with subgroup 2 (CRS 2–3)
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either before or after administration of neoadjuvant che-
motherapy (P = 0.092 and P = 0.505, respectively).
Survival Outcome after Neoadjuvant Chemotherapy
Patients with a lower CRS after neoadjuvant chemo-
therapy, compared to before chemotherapy, had the same
survival outcome as patients with the same score but who did
not have chemotherapy. For Nagashima’s score, patients
with a lower CRS after neoadjuvant chemotherapy had an
even better survival outcome than patients with the same
score who did not undergo chemotherapy (P = 0.009).
DISCUSSION
Until now, CRSs have not been evaluated for patients
undergoing neoadjuvant chemotherapy before resection of
CRLM. The present study evaluated CRSs in patients who
received neoadjuvant chemotherapy before resection of
liver metastases, and in patients who did not receive neo-
adjuvant chemotherapy.
Our results confirm that the CRSs of Nordlinger, Fong,
Nagashima and Konopke could be applied to patients
without neoadjuvant chemotherapy; however, when asses-
sed before neoadjuvant chemotherapy, not all the CRSs are
applicable.
A recent study evaluated eight prognostic scoring sys-
tems whereas we examined only four CRSs.23 Our reason
for not investigating more scoring systems was because we
lacked data on some variables used for these scores. For
example, the score of Ueno et al. uses a pathological factor
‘tumor budding’ which is not reported for all patients in our
clinic.16 Rees et al. include the differentiation of the pri-
mary tumor in the score; however, because we are a
referral center most patients had their primary tumor
resected elsewhere and we were unable to obtain all
information required for this score.14 Schindl et al. use
specific laboratory findings in their score, but these vari-
ables were not available in our prospectively recorded
database.13
Generally, CRSs are not used to determine the possi-
bility of surgery in a patient with CRLM, but mainly to
assess the prognosis of this group of patients after suc-
cessful surgery. To compare results of different studies, it
is helpful to assess outcome with knowledge of disease
severity. The CRSs can be helpful in these cases and are
often used.2,24 However, use of effective neoadjuvant
chemotherapy might influence the value of the widely used
CRSs.
Small et al. hypothesized that the power of prediction of
Fong’s score is reduced as a result of the effects of che-
motherapy.20 To our knowledge, the present study is the
first to explore this hypothesis in a single-center database
with four CRSs in patients treated with neoadjuvant che-
motherapy. Our results support the finding that when the
CRS is calculated before starting neoadjuvant chemother-
apy it is of no predictive value; however, we demon-
strate that the scores are applicable when the score is
addressed after administration of neoadjuvant chemother-
apy. Konopke et al. described 43 patients who received
neoadjuvant chemotherapy.12 In their study, the factors
concerning liver-related oncological status were deter-
mined intraoperatively. Konopke et al. also confirmed the
prognostic value of their scoring system in the patients who
received neoadjuvant chemotherapy. This means that the
score was determined after receiving neoadjuvant chemo-
therapy so one would expect this score to be applicable.
However, we could not demonstrate the same result in our
group of patients.
In the present study, chemotherapy downstaged the size
and the CEA level. When the pathology report was con-
sulted and complete response was reported, then the
number of metastases also decreased significantly from a
mean of 3.19 ± 1.95 to 2.64 ± 1.96 (P \ 0.001). This
effect changes the CRS. Patients who had a higher risk
score before chemotherapy became patients with a lower
risk score after chemotherapy, with an associated improved
survival. Bilobar disease showed no statistically significant
change after administration of neoadjuvant chemotherapy,
and extrahepatic disease did not change at all.
In conclusion, in the era of effective neoadjuvant che-
motherapy, the traditional CRSs may no longer be a
reliable predictive tool. On the basis of our findings, if
prediction of prognosis is required, all the traditional CRSs
can be used if they are determined after treatment with
neoadjuvant chemotherapy. If a prognosis is required
before starting neoadjuvant therapy, only the Nordlinger
CRS is of statistically significant prognostic value.
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